Skip to main content

ICH E11 Clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99)

 ICH E11, titled "Clinical Investigation of Medicinal Products in the Pediatric Population," with the reference number CPMP/ICH/2711/99, is a guideline developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guideline provides recommendations and principles for conducting clinical trials involving pediatric patients to support the development and registration of medicinal products specifically intended for use in children. Here's an elaboration of ICH E11:


1. Purpose:

The primary purpose of ICH E11 is to facilitate the development of safe and effective medicinal products for pediatric patients by providing guidance on the design, conduct, and ethical considerations of clinical trials in this population.

2. Applicability:

ICH E11 is applicable to clinical trials conducted in pediatric populations across various therapeutic areas, including investigational drugs, biologics, and medical devices. It focuses on pediatric patients from birth to 18 years of age.

3. Ethical Considerations:

The guideline places a strong emphasis on the ethical conduct of pediatric clinical trials. It underscores the importance of obtaining informed consent from the parents or legal guardians and, where appropriate, assent from the pediatric subjects themselves.

4. Pediatric Development Plans:

ICH E11 recommends that sponsors develop a pediatric development plan early in the drug development process, outlining the strategy for conducting pediatric trials. The plan should consider the specific age groups and indications for which the product is intended.

5. Age-Appropriate Formulations:

The guideline highlights the need for age-appropriate formulations, such as liquid preparations or age-specific dosing forms, to ensure that the medicinal product can be safely and effectively administered to pediatric patients.

6. Extrapolation of Data:

ICH E11 discusses the concept of data extrapolation, where data from adult trials or older pediatric populations may be used to support the efficacy and safety of the product in younger age groups when scientifically justified.

7. Pediatric Study Designs:

The guideline provides recommendations on pediatric study designs, including considerations for dose selection, endpoints, and statistical approaches appropriate for pediatric trials.

8. Safety Monitoring:

ICH E11 emphasizes the importance of safety monitoring throughout the conduct of pediatric trials. It includes recommendations for adverse event reporting and assessment of safety signals.

9. Bridging Studies:

When appropriate, bridging studies may be conducted to demonstrate that the medicinal product's effects in pediatric patients are similar to those observed in adults.

10. Regulatory Considerations:

- The guideline acknowledges the role of regulatory authorities in reviewing and approving pediatric clinical trial protocols and data. It encourages early and ongoing communication with regulatory agencies.

11. Pediatric Ethics Committees:

- ICH E11 suggests that ethics committees reviewing pediatric trial protocols should include members with expertise in pediatrics or pediatric ethics.

12. Transparency and Data Sharing:

- The guideline highlights the importance of transparency in reporting pediatric clinical trial results and encourages data sharing to benefit the scientific community and pediatric patients.


In summary, ICH E11 provides guidance for the ethical and scientific conduct of clinical trials in pediatric populations. Compliance with this guideline is essential for pharmaceutical companies and investigators involved in the development of medicinal products intended for use in children, ensuring that these products are safe, effective, and appropriately dosed for pediatric patients across different age groups.

Labels:

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

ICH E3 Structure and content of clinical study reports (CPMP/ICH/137/95)

 The ICH E3 guideline, titled "Structure and Content of Clinical Study Reports," with the reference number CPMP/ICH/137/95, provides recommendations and a standardized framework for the structure and content of clinical study reports (CSRs). CSRs are essential documents that summarize the results and findings of clinical trials conducted during the drug development process. Here's an elaboration of ICH E3: 1. Purpose: The primary purpose of ICH E3 is to provide guidance on the organization, content, and format of CSRs to ensure consistency and clarity in reporting clinical trial data. It aims to facilitate the evaluation of the safety and efficacy of investigational drugs by regulatory authorities. 2. Applicability: ICH E3 is applicable to CSRs for all phases of clinical trials, including Phase I, II, III, and post-marketing studies. 3. Structure of the CSR: The guideline outlines a standardized structure for the CSR, which typically includes the following sections: Title...
Read more

ICH 5QC Stability testing of biotechnological/biological products (CPMP/ICH/138/95)

ICH Topic Q5C, as outlined in document CPMP/ICH/138/95, addresses the stability testing of biotechnological and biological products. This guideline provides a framework for assessing the stability of these products over time, ensuring that they maintain their quality, safety, and efficacy throughout their shelf life. Below is an elaboration of ICH Q5C: 1. Purpose of ICH Q5C: The primary purpose of ICH Q5C is to establish principles and guidelines for conducting stability testing of biotechnological and biological products. The goal is to provide evidence that these products remain safe and effective during their intended shelf life. 2. Types of Products Covered: ICH Q5C applies to a wide range of biotechnological and biological products, including monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and other biopharmaceuticals. 3. Stability Study Design: The guideline outlines the design of stability studies, including the selection of relevant storage conditions, ti...
Read more